Sympathomimetic Amine Anorectic Drug Class List

Drugs in Drug Class: Sympathomimetic Amine Anorectic

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vivus Llc	QSYMIA	phentermine hydrochloride; topiramate	CAPSULE, EXTENDED RELEASE;ORAL	022580-002	Jul 17, 2012	AB	RX	Yes	No			Y
Vivus Llc	QSYMIA	phentermine hydrochloride; topiramate	CAPSULE, EXTENDED RELEASE;ORAL	022580-004	Jul 17, 2012	AB	RX	Yes	Yes
Vivus Llc	QSYMIA	phentermine hydrochloride; topiramate	CAPSULE, EXTENDED RELEASE;ORAL	022580-001	Jul 17, 2012	AB	RX	Yes	No			Y
Vivus Llc	QSYMIA	phentermine hydrochloride; topiramate	CAPSULE, EXTENDED RELEASE;ORAL	022580-003	Jul 17, 2012	AB	RX	Yes	No			Y
Vivus Llc	QSYMIA	phentermine hydrochloride; topiramate	CAPSULE, EXTENDED RELEASE;ORAL	022580-002	Jul 17, 2012	AB	RX	Yes	No			Y

Last updated: July 21, 2026

Sympathomimetic Amine Anorectic Drugs: Market Dynamics and Patent Landscape

Executive summary

• The “sympathomimetic amine anorectic” class remains structurally dominated by older, small-molecule appetite suppressants (primarily phentermine and combinations). Patent estates are largely mature, with most meaningful patent protection now expired or close to expiry across major markets.
• Ongoing patent value is concentrated in: (i) formulation and controlled-release improvements, (ii) specific fixed-dose combinations and dosing regimens, and (iii) method-of-use claims tied to particular patient subsets, safety monitoring, or endpoints.
• Commercial dynamics skew to generics and authorized generics, with brand survival depending on remaining exclusivity pockets, pricing, payer contracting, and the regulatory status of each product.
• The highest litigation and entry-risk typically clusters around Orange Book “listed” patents for the latest branded fixed-dose products and newer reformulated versions, rather than the base active ingredients.

---

What drugs are included in the sympathomimetic amine anorectic class and how is the market segmented?

Featured snippet: The class is best represented by appetite suppressants that act primarily through sympathomimetic pathways, with the dominant US competitive set historically led by phentermine-based products and selected fixed-dose combinations.

Core active ingredients and common product archetypes

1. Phentermine (single entity)
   • Short-duration appetite suppressant; long-standing US availability.
2. Phentermine/topiramate fixed-dose combination (Qsymia)
   • Modern branded combination with longer-cycle exclusivity history and formulation-specific patent coverage.
3. Phendimetrazine (single entity)
   • Another older sympathomimetic anorectic.
4. Diethylpropion (single entity)
   • Older sympathomimetic anorectic.
5. Benzphetamine (single entity)
   • Older sympathomimetic anorectic.
6. Pemoline (historical / restricted use in some jurisdictions)
   • Older stimulant anorectic; modern availability varies by geography and risk controls.

Market segmentation by competitive status

• Generic-saturated legacy mono-therapies: Typically driven by low-cost generics, with brand premiums limited to supply stability, managed-care access, and residual formulation exclusivity.
• Fixed-dose branded combinations: Carry the most persistent patent and regulatory “hooks” due to combination-specific and formulation-specific intellectual property.
• Newer weight-loss therapeutic substitution: GLP-1 and dual agonists have reduced the addressable premium tier for sympathomimetics, increasing pressure on pricing and compelling manufacturers to rely on remaining IP and formulary positioning.

Geography

• United States: Orange Book-driven entry risk and FDA exclusivity timelines shape generic uptake.
• Europe: Patent filings and SPC strategy (where applicable) often govern effective exclusivity more than market exclusivity.
• Other markets: Often follow regional patent validity and local regulatory listing for combination products.

---

What patents protect sympathomimetic amine anorectics and how many patents typically matter?

Featured snippet: Patent relevance usually concentrates in Orange Book-listed patents that cover the marketed formulation, composition, combination ratios, and specific method-of-use claims.

Patent categories that most often cover the “real” barriers to generic entry

1. Composition of matter (active ingredient or salt forms)
   • For these older actives, most original composition patents are generally long expired in major markets.
2. Formulation patents
   • Controlled-release matrices, bead-in-capsule systems, dissolution profiles, and stability claims.
3. Combination patents
   • Fixed-dose ratios, titration regimens, and patient stratifications.
4. Method-of-use patents
   • Dosing regimens tied to weight-loss outcomes, BMI endpoints, or safety monitoring frameworks.
5. Manufacturing/process patents
   • Granulation, coating, and scale-up processes that can be used to resist non-infringing process design-arounds.

How many patents typically matter in practice?

• For legacy mono-therapies: few-to-zero listed patents with enforceable scope at present in most jurisdictions.
• For modern branded combinations: the number of Orange Book-listed patents that remain “in play” around launch windows can be higher, especially where formulation, method-of-use, and combination claims are layered.

---

When do sympathomimetic anorectics lose exclusivity, and what drives the clock?

Featured snippet: Exclusivity and patent expiry depend on the specific marketed product; for older mono-therapies, practical exclusivity is largely ended, while combination and reformulated products still show staggered expiry by patent family and listing.

What determines the exclusivity timeline

1. Core patent expiry
2. Patent term adjustments (PTA) and patent term extensions (Europe/SPC)
3. Regulatory exclusivity
   • Orphan, new chemical entity, and 505(b)(2) exclusivities are product-specific; sympathomimetic anorectics are more often governed by patent rather than exclusivity.
4. Orange Book “listed” patent expiration sequencing
   • The generic filing strategy depends on whether a product can avoid each listed patent by design or by noninfringement.
5. Market exclusivity practicalities
   • Even after patent expiry, authorized generic arrangements, payer contracting, and supply chain economics can delay erosion.

Typical pattern in this class

• Phentermine and most older stimulants: mostly long-expired patent families; generic dominance is structural.
• Fixed-dose branded combinations (notably phentermine/topiramate): historically had longer tails due to combination and formulation patent families, with staggered loss across dosages and release technologies.

---

What is the Orange Book status of the main sympathomimetic amine anorectic products?

Featured snippet: Orange Book status dictates whether a generic faces Paragraph IV hurdles. For most legacy sympathomimetics, Orange Book-listed patents are either expired or narrow; for branded fixed-dose combinations, listed patents often concentrate in formulation and method-of-use.

Orange Book-driven product behavior

• If listed patents have expired: ANDA approvals can proceed on “no patent” dates.
• If listed patents remain: ANDA applicants must navigate:
  • Section viii (skinny labeling) for method-of-use carveouts, or
  • Paragraph IV certifications for invalidity/noninfringement, or
  • Design-around strategies (different release profile, different excipient system, different ratio, or different dosing regimen).

Litigation correlation

• Orange Book product listings correlate strongly with Paragraph IV filings and settlements for the class, especially where method-of-use or formulation patents remain asserted near the generic entry window.

---

Which companies are challenging sympathomimetic anorectic patents via Paragraph IV, and what are the litigation outcomes?

Featured snippet: Generic applicants usually challenge the remaining Orange Book-listed patents for branded fixed-dose products first, with litigation outcomes often resolving via settlement rather than final merits verdicts.

Typical litigation pattern in this class

1. Paragraph IV certifications filed close to the last listed patent expiry
2. Hatch-Waxman 30-month stay pending litigation
3. Settlement agreements
   • Common structure: branded company grants a “no launch until” date tied to a specified patent expiry, often with carveouts for dosage strengths or authorized product forms.

What tends to determine outcome strength

• Claim construction strength in formulation patents (release profile and excipient mapping)
• Whether generic labels and dosing match the asserted method-of-use claims
• Whether the accused product is “equivalent” in physicochemical properties

---

How strong is the patent estate for phentermine-based and fixed-dose sympathomimetic anorectics?

Featured snippet: Patent strength is highest for branded fixed-dose combinations with layered formulation and method-of-use claims; legacy mono-therapies typically have limited enforceable value due to expired core families.

Patent strength drivers by claim type

1. Formulation claims
   • Strong when claim language is tied to measurable properties (dissolution, release kinetics) with clear infringement tests.
2. Method-of-use claims
   • Strong when tied to specific dosing or patient-response monitoring that is likely to appear in labeling.
3. Combination ratio claims
   • Strong when generics must copy the fixed-dose ratio and dosing schedule.
4. Composition-of-matter claims
   • Weak now for most older actives if original patents are expired, barring new salts/polymorphs.

Business impact

• Strongest estates typically control:
  • Generic launch timing
  • Skinny-label availability
  • Authorized generic entry
  • Dosage-strength rollout sequencing

---

What generic entry risks exist for sympathomimetic amine anorectics?

Featured snippet: Main risks are tied to whether a branded product still has unexpired Orange Book-listed patents and whether a generic can carve out method-of-use language or design around formulation claims.

Entry risk map

• Legacy mono-therapies: low patent barrier, high competition from generics. Primary risks are supply and pricing, not exclusivity.
• Branded fixed-dose combinations: medium-to-high patent barrier if formulation and method-of-use patents remain listed.
• Reformulated or newer strength presentations: higher risk if they have separate formulation patents and separate dosing instruction language.

Likely generic strategies

1. Carveout labeling (skinny label)
2. Paragraph IV with settlement
3. Design-around (different release and excipient matrix)
4. Authorized generic
   • Branded company may maintain market share via licensing while monetizing remaining patent value.

---

How do sympathomimetic anorectics compare with newer anti-obesity drugs in terms of IP and competitive pressure?

Featured snippet: GLP-1 and dual agonists carry large and active patent estates but operate in a different mechanistic and regulatory segment; sympathomimetics face competitive displacement rather than direct IP overlap.

Mechanistic substitution effects

• Payers and formularies have increasingly positioned modern anti-obesity drugs above sympathomimetic monotherapies, especially where clinical outcomes favor newer agents.
• This reduces revenue potential and raises the stakes for each remaining branded life-year in the sympathomimetic segment.

IP overlap dynamics

• Direct patent infringement overlap is uncommon because products differ by MOA and molecular entities.
• The IP interaction is indirect: competitive shelf-space and contracting decisions shape the practical monetization window of remaining sympathomimetic IP.

---

What formulations are protected in sympathomimetic anorectics, and what design-arounds are plausible?

Featured snippet: Formulation patents typically protect controlled-release profiles, stability, and tablet/capsule engineering that drive dissolution and release kinetics.

Common protected formulation themes

• Controlled-release matrices and coating systems
• Excipient selections affecting release and bioavailability
• Dosage-strength specific unit operations and manufacturing parameters

Design-around levers

• Altering release technology (e.g., different coating system or matrix approach)
• Changing dissolution-release targets and demonstrating non-infringement with comparative data
• Using different unit dose configurations to avoid literal or doctrine-of-equivalents coverage

Infringement hot spots

• Tests and specs tied to claim language
• Physicochemical comparability that makes generics “too close” to the branded product

---

How do method-of-use patents affect labeling, coding, and ANDA “skinny label” strategies?

Featured snippet: Method-of-use claims are enforceable barriers when generic applicants must copy labeling language or cannot safely carve out the asserted indications/dosing regimens.

Label dependencies

• If the asserted method-of-use language is broadly written, skinny labeling is harder.
• If the claims are narrow to a patient subgroup, a specific BMI threshold, or specific endpoint goals, carveouts become more viable.

Litigation implications

• Method-of-use disputes frequently revolve around:
  • Whether the accused ANDA labeling infringes
  • Whether the branded labeling is the same as in the claim scope
  • Whether the generic’s instructions “induce” the claimed use

---

What FDA regulatory pathway and exclusivity mechanics matter for this class?

Featured snippet: Most generics enter via ANDA under 21 U.S.C. §355(j), with the primary exclusivity mechanics governed by Orange Book-listed patents and any applicable 505(b)(2) framework for branded reformulations.

Practical FDA mechanics that drive timing

• Orange Book “listed” patents govern the statutory stay and certification structure.
• 505(b)(2) reformulations can introduce new listed patents if they rely on new studies or modified formulations.

Safety and controlled substance considerations

• Many sympathomimetic anorectics are controlled substances or subject to restricted prescribing. These controls can affect market access but do not eliminate patent barriers.

---

What settlement agreements and licensing deals have shaped the market for sympathomimetic anorectics?

Featured snippet: The class’s branded-to-generic transition often resolves via settlements tying generic entry to specific patent expiry dates and sometimes splitting by dosage strength.

Settlement structures commonly used

• “No launch before” dates tied to the last-to-expire relevant patent
• Carveouts for strengths not covered by the asserted claims
• Mutual non-assignment of certain rights, with ongoing support for remaining products

Licensing as an alternative to continued litigation

• Authorized generic licensing can preserve branded revenue while avoiding further discovery and trial risk.
• This reduces the generic brand risk profile for the challenger and stabilizes supply economics.

---

Key takeaways

• Patent protection for sympathomimetic amine anorectics is generally concentrated in formulation, fixed-dose combination, and method-of-use layers rather than foundational composition-of-matter claims, which are largely mature for legacy mono-therapies.
• Market share shifts faster than IP expiry for older actives because generic saturation is structural.
• For branded fixed-dose products, the decisive questions are Orange Book listings, remaining formulation and method-of-use patents, and whether generic applicants can implement skinny labeling or design-arounds.
• Competitive pressure from GLP-1 and dual agonists reduces revenue upside in this class, raising reliance on any remaining IP tail and on payer access strategy to defend cash flow.

---

FAQs

1. Which sympathomimetic anorectic products still have unexpired Orange Book-listed patents in the US?
2. How do controlled-release formulation patents change ANDA design-around options for anorectic stimulants?
3. What is the typical settlement “no launch before” structure in Hatch-Waxman cases involving appetite suppressants?
4. Do method-of-use claims for weight-loss dosing regimens materially affect skinny-label acceptance?
5. How does the rise of GLP-1-based anti-obesity therapies affect prescribing volume and branded patent monetization for sympathomimetic anorectics?

---

References

1. US Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (FDA).
2. US Food and Drug Administration. Drug Approval Packages and Labeling (for relevant NDA/BLA products). (FDA).
3. US Code. 21 U.S.C. §355 (Hatch-Waxman provisions for ANDAs and paragraph IV certifications).